Meeting Coverage
ASRS
American Society of Retina Specialists
Also from ASRS: gene therapy for retinitis pigmentosa, anti-VEGF implant matches injection
Latest ASRS Meetings
Longer treatment-free interval with similar vision outcomes versus aflibercept in neovascular AMD
Reoperation rate reduced by three fourths, use expanded to advanced diabetic retinopathy
Subretinal drusenoid deposits found in 85% of patients with AMD and CVD in small study
Reduced treatment burden, durable therapeutic effects with aflibercept-expressing construct
Clearing out dying cells, approach has implications far beyond ophthalmology
Progression slowed by 27-30% at 12 and 18 months with avacincaptad versus sham control
Similar visual acuity and safety with potential for extended dosing interval
Implant matches monthly injections for efficacy with 6-month refill schedule
Three cases of irreversible vision loss, high rate of intraocular inflammation
Significant improvement in vision, retinal thickening after inadequate response to anti-VEGF
No clear link to endophthalmitis after ophthalmologic procedure -- yet
Refill with anti-VEGF therapy pushed to 15 months
Bi-specific antibody, integrin inhibitor move to phase III